Zoster Meningitis – A Complete Patient‑Friendly Guide

Overview

Zoster meningitis is inflammation of the meninges (the protective membranes covering the brain and spinal cord) caused by the reactivation of the varicella‑zoster virus (VZV), the same virus that produces chicken‑pox and shingles. When VZV reactivates, it can travel along nerve roots and invade the cerebrospinal fluid (CSF), leading to meningitis.

Although VZV is a well‑known cause of shingles, it accounts for only 0.5–5 % of all viral meningitis cases in adults (CDC, 2023). The condition is most common in:

• Adults ≥ 50 years old – immune‑senescence lowers VZV‑specific immunity.
• People with weakened immune systems (e.g., HIV, organ‑transplant recipients, cancer chemotherapy).
• Individuals who have had recent shingles (especially when the rash is near the head or neck).

Overall, VZV meningitis is considered rare; estimates suggest 1–2 cases per 100,000 population annually in the United States, but incidence rises sharply after age 60 (Mayo Clinic, 2024).

Symptoms

Symptoms usually appear 1–3 weeks after shingles onset, but can develop without a preceding rash (“zoster sine herpete”). Common manifestations include:

General

• Headache – often described as dull, pressure‑like, worsening when lying down.
• Fever – low‑grade (≥ 38 °C) or high‑grade spikes.
• Neck stiffness – difficulty bending the neck forward, a classic sign of meningeal irritation.
• Photophobia – increased sensitivity to light.
• Fatigue & malaise – generalized weakness that may last weeks.

Neurological

• Altered mental status – confusion, lethargy, or difficulty concentrating.
• Vomiting – often non‑bilious and not related to food intake.
• Seizures – uncommon but possible, especially in immunocompromised patients.
• Focal neurological deficits – weakness or numbness in a limb, facial droop, or ataxia.

Cutaneous (when a rash is present)

• Unilateral vesicular rash following a dermatome, most often on the torso, face, or scalp.
• Rash may precede meningitis by days to weeks, or may be absent entirely.

Causes and Risk Factors

VZV lies dormant in sensory ganglia after primary infection (chicken‑pox). Reactivation triggers viral replication and spread to the meninges.

Primary Causes

• Reactivation of latent VZV – triggered by cellular immunity decline.
• Direct extension from shingles lesions – especially when lesions involve the cranial nerves or thoracic dermatomes near the spinal cord.
• Hematogenous spread – rare, usually in severely immunocompromised patients.

Risk Factors

• Age ≥ 50 years (immune senescence).
• Immunosuppression (HIV/AIDS, chemotherapy, chronic steroids, organ transplant).
• Chronic illnesses: diabetes mellitus, chronic kidney disease, malignancy.
• Recent or severe shingles outbreak, particularly involving the face (V1 branch of trigeminal nerve).
• Stress, trauma, or other events that dampen cellular immunity.

Diagnosis

Prompt diagnosis is essential because antiviral therapy reduces neurologic sequelae.

Clinical Evaluation

• Detailed history – recent shingles, immunization status, underlying diseases.
• Physical exam – meningeal signs (neck rigidity, Kernig’s and Brudzinski’s), rash assessment, neurological testing.

Laboratory & Imaging Tests

1. Lumbar Puncture (LP)
   • Opening pressure: often mildly elevated.
   • CSF analysis:
     • Clear or slightly turbid fluid.
     • White blood cell count 50–500 cells/µL, predominantly lymphocytes.
     • Protein ↑ (50–150 mg/dL).
     • Glucose normal or mildly reduced.
   • VZV PCR – gold standard; detects viral DNA in > 95 % of confirmed cases.
   • CSF VZV IgM/IgG antibodies – supportive but less specific.
2. Blood Tests
   • Complete blood count, metabolic panel.
   • Serum VZV IgM/IgG – useful if CSF unavailable.
3. Neuroimaging
   • Contrast‑enhanced MRI of brain and spine – rules out alternative causes (abscess, tumor) and may show meningeal enhancement.
   • CT scan only if MRI contraindicated or acute neuro‑emergence suspected.

Treatment Options

Therapy combines antiviral medication, symptomatic care, and, when indicated, adjunctive steroids.

Antiviral Therapy

• Acyclovir 10–15 mg/kg IV every 8 hours for 10–14 days (CDC, 2023). Oral valacyclovir is an alternative for mild cases or after IV completion.
• If acyclovir-resistant (rare, often in HIV), consider foscarnet 60 mg/kg IV q12h.
• Early initiation (within 72 h of symptom onset) is associated with faster recovery and fewer sequelae.

Adjunctive Therapy

• Corticosteroids – dexamethasone 10 mg IV loading dose then 4 mg q6h for 4 days may reduce inflammation, but evidence is mixed; used at clinician discretion.
• Pain control – NSAIDs or acetaminophen; consider gabapentin if neuropathic pain persists.
• Supportive care – hydration, antipyretics, anti‑emetics.

Lifestyle & Home Measures

• Bed rest during acute phase; avoid strenuous activity.
• Maintain adequate fluid intake (≥2 L/day) to aid CSF turnover.
• Monitor temperature and neurological status twice daily.

Living with Zoster Meningitis

Recovery can take weeks to months. Below are practical tips to ease daily life.

Post‑Acute Recovery

• Gradual activity increase – start with short walks; avoid lifting > 10 lb for the first 2 weeks.
• Sleep hygiene – aim for 7–9 hours; use a dark, quiet room to lessen photophobia.
• Nutrition – balanced diet rich in vitamins A, C, D and zinc to support immune function.
• Vaccination – receive the recombinant zoster vaccine (Shingrix) after recovery if not already immunized.

Managing Persistent Symptoms

• Neuropathic pain: gabapentin 300 mg TID or pregabalin 75 mg BID.
• Headache: scheduled acetaminophen plus a short course of NSAIDs; avoid medication overuse.
• Memory or concentration issues: cognitive exercises, short “brain breaks,” and, if needed, referral to neuro‑rehab.

Follow‑up Care

• Repeat lumbar puncture is rarely needed; a follow‑up MRI is indicated if symptoms persist > 4 weeks.
• Regular appointments with primary care or infectious‑disease specialist every 1–2 months until full resolution.

Prevention

Because VZV reactivation is the root cause, preventing initial infection and reducing reactivation risk are key.

• Vaccination – Recombinant zoster vaccine (Shingrix) is > 90 % effective at preventing shingles and post‑herpetic neuralgia; CDC recommends it for adults ≥ 50 years, and for immunocompromised adults ≥ 19 years.
• Maintain immune health – adequate sleep, balanced diet, regular moderate exercise, stress‑reduction techniques.
• Control chronic diseases – good glycemic control, blood pressure management, and adherence to HIV antiretroviral therapy.
• Avoid exposure to varicella – pregnant women and immunocompromised individuals should stay away from people with active chicken‑pox.
• Prompt treatment of shingles with antivirals (within 72 h) reduces the chance of VZV meningitis.

Complications

If untreated or inadequately treated, VZV meningitis can lead to serious outcomes:

• Encephalitis – inflammation of brain tissue, causing seizures, focal deficits, or coma.
• Vasculopathy – VZV‑induced inflammation of cerebral arteries → stroke.
• Chronic meningitis – persistent CSF inflammation causing ongoing headache and cognitive decline.
• Hydrocephalus – impaired CSF absorption leading to increased intracranial pressure.
• Post‑herpetic neuralgia – severe, long‑lasting pain after rash resolution, reported in up to 30 % of older adults with shingles.
• Rarely, mortality – higher in immunosuppressed patients (estimated 5–10 % mortality if severe encephalitis develops).

When to Seek Emergency Care

---

References:
1. Centers for Disease Control and Prevention. “Varicella‑Zoster Virus (VZV) Meningitis.” 2023.
2. Mayo Clinic. “Viral meningitis.” Updated 2024.
3. National Institutes of Health, National Institute of Allergy and Infectious Diseases. “Guidelines for the Management of Herpes Zoster.” 2022.
4. Cleveland Clinic. “Shingles (Herpes Zoster) and its Complications.” 2023.
5. World Health Organization. “Recommendations for the Use of Recombinant Zoster Vaccine.” 2024.